SciELO - Scientific Electronic Library Online

vol.14 issue2An interstitial lung disease (ILD) belongs to a group of diffuse parenchymal lung diseasesPhysiopathology of cartilage and base for future therapies in early osteoarthritis author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Revista Colombiana de Reumatología

Print version ISSN 0121-8123


GOMEZ PUERTA, José A. Fifteen years of the catastrophic antiphospholipid syndrome: What have we learned?. Rev.Colomb.Reumatol. [online]. 2007, vol.14, n.2, pp.129-134. ISSN 0121-8123.

The catastrophic antiphospholipid syndrome (APS) was described 15 years ago as a potentially life threatening variant of presentation of APS. Catastrophic APS is characterized by clinical evi-dence of multiple organ involvement developed over a very short time period and histopathological evidence of multiple small vessel occlusions. An early recognition of potential triggers such as infections, surgery, traumatisms or lupus "flares" is mandatory in these patients. The combination of high doses of intravenous (iv) heparin, iv steroids, iv gammaglobulins and/or repeated plasma exchanges is the basic treatment of choice for all patients with this severe condition. The survival rate of catastrophic APS patients have improved during last years, however, global mortality is around 50%.

Keywords : Antiphospholipid antibodies; catastro-phic antiphospholipid syndrome; Multiorganic failure.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License